SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (NASDAQ: REPL)

Group 1 - A shareholder has filed a securities class action lawsuit against Replimune Group, Inc. and certain senior officers, alleging violations of the Securities Exchange Act of 1934 for the period between November 22, 2024, and July 21, 2025 [1] - The lawsuit claims that the defendants made misrepresentations regarding the IGNYTE trial's prospects for RP1, a cancer drug, in combination with nivolumab for treating advanced melanoma [3] Group 2 - Replimune's lead drug product candidate is RP1, which is focused on cancer treatment [3] - The law firm Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [5]